Strides Pharma Consolidates European Business-to-Business Operations in Switzerland
- Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
- Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board

Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.
Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.
The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.
Oren Weininger, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”
Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.
For further information, please visit: www.fair-med.com/newsroom
Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690
Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.
Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.
Images

Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press release
Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
Dr. Stefanie Kesting appointed as CEO of Thyssengas7.1.2026 14:06:26 CET | Press release
Dortmund, 06.01.2026 As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:59:31 CET | Press release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom